🇺🇸 FDA
Pipeline program

Vialed Saline Placebo, ALXN2030

ALXN2030-AMR-201

Phase 2 small_molecule active

Quick answer

Vialed Saline Placebo, ALXN2030 for Antibody-Mediated Rejection after Kidney Transplantation is a Phase 2 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
Antibody-Mediated Rejection after Kidney Transplantation
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials